Compare Li Auto Inc (LI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Twist Bioscience Corp — how do they compare? Li Auto Inc trades at $12.59 (market cap $12.54B), while Twist Bioscience Corp trades at $123.01 (market cap $7.82B). The key difference: Li Auto Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | TWST | |
|---|---|---|
Market Cap | $12.54B | $7.82B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.69 | $124.88 |
52-Week Low | $11.74 | $24.16 |
Enterprise Value | $1.37B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.95, up 2.05% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries show modest growth, with 30,468 vehicles delivered in July 2026. Analyst consensus remains divided with a $14.80 price target, suggesting potential upside from current levels despite near-term challenges.
The outlook for LI is cautious with revenue contraction and profitability pressures, though the EV market in China offers long-term growth potential. Key risks include intense domestic competition and execution challenges with new vehicle launches. Investment opportunity exists if the company can stabilize margins and regain growth momentum, supported by analyst optimism for recovery from 2027 onwards.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
